CSL Behring Discontinues Production and Distribution of Monoclate-P®

VIA The National Hemophilia Foundation:
CSL Behring has announced that due to patients transitioning from plasma-derived to recombinant products, it has been difficult to sustain the production and distribution of Antihemophilic Factor Monoclate-P® Factor VIII:C Pasteurized Monoclonal Antibody Purified. Therefore production of Monoclate-P® will be discontinued, and CSL Behring estimates that existing supplies will only be available until December 2018.

If you are currently using Monoclate-P®, please contact your physician or hemophilia treatment center to learn about other options that are available to you for treatment.


Leave a Reply

About Us

The Hemophilia Foundation of Michigan strives to improve the quality of life for all people affected by hemophilia, von Willebrand disease, other coagulation disorders, and related complications.

Recent Posts

It’s a Great Time to Review Your Insurance Plan for 2019

A few things to keep in mind! Do you depend on factor co-pay assistance? If so, you should know that some insurance plans have changed …

Read More →

What is an Accumulator Adjustment Program?

Beginning January 2018, a few health plans, specifically high deductible plans offered by self-insured employer groups, have changed the way they calculate copays for patients using these cards.

Read More →

Follow Us

Sign up for our Newsletter

Get all the latest updates and news from  HFM

  • This field is for validation purposes and should be left unchanged.
Skip to content